[
  {
    "ts": null,
    "headline": "Ranking the S&P 500s Most Defensive Stocks",
    "summary": "Ranking the S&P 500s Most Defensive Stocks",
    "url": "https://finnhub.io/api/news?id=613bb997a3e5c54ea9dc76a12377fe96e5277ef4d06ef15cb60e6fd12dca72e5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742583720,
      "headline": "Ranking the S&P 500s Most Defensive Stocks",
      "id": 133313897,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Ranking the S&P 500s Most Defensive Stocks",
      "url": "https://finnhub.io/api/news?id=613bb997a3e5c54ea9dc76a12377fe96e5277ef4d06ef15cb60e6fd12dca72e5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson is the latest pharma giant to court Trump with new investment plans",
    "summary": "Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing plans to expand its manufacturing footprint in the United States.",
    "url": "https://finnhub.io/api/news?id=61380143af7912ad9416c2eac76e3412432b20c8c15c3f858922b0007b2eab15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742582460,
      "headline": "Johnson & Johnson is the latest pharma giant to court Trump with new investment plans",
      "id": 133324404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing plans to expand its manufacturing footprint in the United States.",
      "url": "https://finnhub.io/api/news?id=61380143af7912ad9416c2eac76e3412432b20c8c15c3f858922b0007b2eab15"
    }
  },
  {
    "ts": null,
    "headline": "J&J boosts US operations with $55bn investment",
    "summary": "J&J is the latest pharma company to announce a major US investment, committing to a $55bn influx in the next four years.",
    "url": "https://finnhub.io/api/news?id=7a65e0059b24231e149f98b7438f30ef684562e067d57495a098a20edb36d55e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742581367,
      "headline": "J&J boosts US operations with $55bn investment",
      "id": 133324549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J is the latest pharma company to announce a major US investment, committing to a $55bn influx in the next four years.",
      "url": "https://finnhub.io/api/news?id=7a65e0059b24231e149f98b7438f30ef684562e067d57495a098a20edb36d55e"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Boeing Wins Multibillion Dollar Contract to Build Fighter Jet; FedEx Shares Fall on Earnings Miss, Downbeat Guidance",
    "summary": "All three major US stock indexes were down in midday trading as markets appear as though they will e",
    "url": "https://finnhub.io/api/news?id=f84721190bd706c44fac4d7aa058fe33aa98202e607162d828132a1b231d6230",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742572897,
      "headline": "Top Midday Stories: Boeing Wins Multibillion Dollar Contract to Build Fighter Jet; FedEx Shares Fall on Earnings Miss, Downbeat Guidance",
      "id": 133324550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were down in midday trading as markets appear as though they will e",
      "url": "https://finnhub.io/api/news?id=f84721190bd706c44fac4d7aa058fe33aa98202e607162d828132a1b231d6230"
    }
  },
  {
    "ts": null,
    "headline": "J&J is latest company trying to get on Trump's good side with big U.S. investment",
    "summary": "Investing.com -- Pharmaceutical giant Johnson&Johnson became the latest company to announce a massive investment in the U.S. to appease President Donald Trump.",
    "url": "https://finnhub.io/api/news?id=228394d857ce67abf4e7d2bbc9f521c4f578f26a8c4ceeec7358fb660e53e559",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742569559,
      "headline": "J&J is latest company trying to get on Trump's good side with big U.S. investment",
      "id": 133324551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- Pharmaceutical giant Johnson&Johnson became the latest company to announce a massive investment in the U.S. to appease President Donald Trump.",
      "url": "https://finnhub.io/api/news?id=228394d857ce67abf4e7d2bbc9f521c4f578f26a8c4ceeec7358fb660e53e559"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Boosts Planned US Investment to More Than $55 Billion",
    "summary": "Johnson & Johnson (JNJ) said Friday that it plans to increase its US investment to more than $55 bil",
    "url": "https://finnhub.io/api/news?id=a8823a82e27c066aad1ff0859bb627c429ca3bbb288561cca16d2f3a18f33fcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742569486,
      "headline": "Johnson & Johnson Boosts Planned US Investment to More Than $55 Billion",
      "id": 133324552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) said Friday that it plans to increase its US investment to more than $55 bil",
      "url": "https://finnhub.io/api/news?id=a8823a82e27c066aad1ff0859bb627c429ca3bbb288561cca16d2f3a18f33fcd"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years",
    "summary": "Johnson & Johnson said it is increasing U.S investments to more than $55 billion over the next four years, boosting spending on manufacturing, R&D and technology.",
    "url": "https://finnhub.io/api/news?id=fb80e8f0f59635bf6b77b9606fe0354d769da6f0fcf1d7371726905854f48239",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742566140,
      "headline": "Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years",
      "id": 133324553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson said it is increasing U.S investments to more than $55 billion over the next four years, boosting spending on manufacturing, R&D and technology.",
      "url": "https://finnhub.io/api/news?id=fb80e8f0f59635bf6b77b9606fe0354d769da6f0fcf1d7371726905854f48239"
    }
  },
  {
    "ts": null,
    "headline": "2025 Dividend Kings: Strong Run Continues",
    "summary": "Discover the top-performing Dividend Kings of 2025, outperforming the S&P 500 by 4.57%. Click here to explore more promising picks.",
    "url": "https://finnhub.io/api/news?id=a74c64a6727c91e36bd84f432d4b5654822919d70d02376d5d8c3b53f8bfe7c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742561991,
      "headline": "2025 Dividend Kings: Strong Run Continues",
      "id": 133307231,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178712905/image_2178712905.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover the top-performing Dividend Kings of 2025, outperforming the S&P 500 by 4.57%. Click here to explore more promising picks.",
      "url": "https://finnhub.io/api/news?id=a74c64a6727c91e36bd84f432d4b5654822919d70d02376d5d8c3b53f8bfe7c7"
    }
  },
  {
    "ts": null,
    "headline": "Investing in the U.S.: Tracking Corporate Spending Pledges Under Trump",
    "summary": "Johnson & Johnson said Friday it would invest more than $55 billion in the U.S. in the next few years, adding to a series of commitments by big corporations.  ? CMA CGM: The French shipping company, led by Rodolphe Saadé, aims to invest $20 billion in the U.S., creating 10,000 jobs. CMA CGM will triple its U.S.-flagged fleet, upgrade port facilities and create a Chicago airfreight hub.  ? Eli Lilly: The drugmaker behind Zepbound and Mounjaro plans to invest $27 billion building four new manufacturing plants in the U.S. Lilly expects the project will create 3,000 high-skilled jobs and employ 10,000 construction workers.",
    "url": "https://finnhub.io/api/news?id=2c997d6f27b81d7557e00fc6aeee21425430a0562844d61c33ef7be043a68345",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742560994,
      "headline": "Investing in the U.S.: Tracking Corporate Spending Pledges Under Trump",
      "id": 133324554,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson said Friday it would invest more than $55 billion in the U.S. in the next few years, adding to a series of commitments by big corporations.  ? CMA CGM: The French shipping company, led by Rodolphe Saadé, aims to invest $20 billion in the U.S., creating 10,000 jobs. CMA CGM will triple its U.S.-flagged fleet, upgrade port facilities and create a Chicago airfreight hub.  ? Eli Lilly: The drugmaker behind Zepbound and Mounjaro plans to invest $27 billion building four new manufacturing plants in the U.S. Lilly expects the project will create 3,000 high-skilled jobs and employ 10,000 construction workers.",
      "url": "https://finnhub.io/api/news?id=2c997d6f27b81d7557e00fc6aeee21425430a0562844d61c33ef7be043a68345"
    }
  },
  {
    "ts": null,
    "headline": "J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease",
    "summary": "FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.",
    "url": "https://finnhub.io/api/news?id=3bc107610bea84887c31038912ce021fe33f80792063c32a0c1887b3ae30560d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742560080,
      "headline": "J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease",
      "id": 133324555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.",
      "url": "https://finnhub.io/api/news?id=3bc107610bea84887c31038912ce021fe33f80792063c32a0c1887b3ae30560d"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease",
    "summary": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV) induction options, for adults with moderately to severely active Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract. This approval is supported by results from multiple Phase 3 trials evaluating more than 1,300 patients with moderately to severely active CD who fa",
    "url": "https://finnhub.io/api/news?id=be24f48a00611aba90756ee6b760f23d9c7a91354e3cbe5f695743ed8ed0275a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742559816,
      "headline": "FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease",
      "id": 133324556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV) induction options, for adults with moderately to severely active Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract. This approval is supported by results from multiple Phase 3 trials evaluating more than 1,300 patients with moderately to severely active CD who fa",
      "url": "https://finnhub.io/api/news?id=be24f48a00611aba90756ee6b760f23d9c7a91354e3cbe5f695743ed8ed0275a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson plans $55 billion in US investments over the next four years",
    "summary": "Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants.  A number of companies have highlighted investments in the U.S. in recent months, a focus of Trump administration.  J&J rival Eli Lilly and Co. announced in late February that it planned to build four new factories in the U.S. Both Lilly and J&J cited tax cut legislation passed in 2017 as factors in their U.S. investments.",
    "url": "https://finnhub.io/api/news?id=1bf0d5a8f74df378b4c9caa68ad238a14fe3f228addbcef370983bc0895db2b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742557296,
      "headline": "Johnson & Johnson plans $55 billion in US investments over the next four years",
      "id": 133324557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants.  A number of companies have highlighted investments in the U.S. in recent months, a focus of Trump administration.  J&J rival Eli Lilly and Co. announced in late February that it planned to build four new factories in the U.S. Both Lilly and J&J cited tax cut legislation passed in 2017 as factors in their U.S. investments.",
      "url": "https://finnhub.io/api/news?id=1bf0d5a8f74df378b4c9caa68ad238a14fe3f228addbcef370983bc0895db2b5"
    }
  },
  {
    "ts": null,
    "headline": "How Understanding Bankruptcy Trends Can Benefit Your Business",
    "summary": "The bankruptcy legal landscape presents both challenges and opportunities for businesses navigating financial distress. Understanding current bankruptcy trends can help businesses make more informed...",
    "url": "https://finnhub.io/api/news?id=3e3f925a3d1d99705490011350730ff8e1146a96a43ef40066d84a185164848d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742551872,
      "headline": "How Understanding Bankruptcy Trends Can Benefit Your Business",
      "id": 133300109,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "The bankruptcy legal landscape presents both challenges and opportunities for businesses navigating financial distress. Understanding current bankruptcy trends can help businesses make more informed...",
      "url": "https://finnhub.io/api/news?id=3e3f925a3d1d99705490011350730ff8e1146a96a43ef40066d84a185164848d"
    }
  },
  {
    "ts": null,
    "headline": "J&J boosts US manufacturing as big pharma reshores",
    "summary": "Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.",
    "url": "https://finnhub.io/api/news?id=a5b94d3386c3a1ab101645633cfbbef145b53e3f83a49126f7c268af43b1841b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742551733,
      "headline": "J&J boosts US manufacturing as big pharma reshores",
      "id": 133324558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.",
      "url": "https://finnhub.io/api/news?id=a5b94d3386c3a1ab101645633cfbbef145b53e3f83a49126f7c268af43b1841b"
    }
  },
  {
    "ts": null,
    "headline": "J&J boosts US investments by 25% over 4 years amid looming tariff threats",
    "summary": "Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a threat of drug import duties by the Trump administration compels companies to expand their manufacturing operations domestically.  The pharmaceutical giant said on Friday it planned to build four new plants as part of its investment, one of which would be set up in Wilson, North Carolina, where it officially broke ground earlier in the day.  J&J did not disclose where it plans to build the other plants.",
    "url": "https://finnhub.io/api/news?id=90f9b9fc3edebdc1dc3eb7be80dd1d1f9b1e5ce241d1ac82c748ecd1f73b7542",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742551673,
      "headline": "J&J boosts US investments by 25% over 4 years amid looming tariff threats",
      "id": 133324559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a threat of drug import duties by the Trump administration compels companies to expand their manufacturing operations domestically.  The pharmaceutical giant said on Friday it planned to build four new plants as part of its investment, one of which would be set up in Wilson, North Carolina, where it officially broke ground earlier in the day.  J&J did not disclose where it plans to build the other plants.",
      "url": "https://finnhub.io/api/news?id=90f9b9fc3edebdc1dc3eb7be80dd1d1f9b1e5ce241d1ac82c748ecd1f73b7542"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years",
    "summary": "NEW BRUNSWICK, N.J., March 21, 2025--Today, Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the Company’s already elevated U.S. investment levels resulting from the passage of the 2017 Tax C",
    "url": "https://finnhub.io/api/news?id=2ed3e67edd135012e64454c6d2fd9bf608db18d661281d044d390bb0f9a7b046",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742551200,
      "headline": "Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years",
      "id": 133324560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., March 21, 2025--Today, Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the Company’s already elevated U.S. investment levels resulting from the passage of the 2017 Tax C",
      "url": "https://finnhub.io/api/news?id=2ed3e67edd135012e64454c6d2fd9bf608db18d661281d044d390bb0f9a7b046"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease",
    "summary": "The decision is based on outcomes from Phase III trials involving 1,300 CD subjects.",
    "url": "https://finnhub.io/api/news?id=29c5fa84e62fb3c77a1223945c33fc3221ffa82037941ebbd97db47490beb370",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742548828,
      "headline": "FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease",
      "id": 133324561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The decision is based on outcomes from Phase III trials involving 1,300 CD subjects.",
      "url": "https://finnhub.io/api/news?id=29c5fa84e62fb3c77a1223945c33fc3221ffa82037941ebbd97db47490beb370"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease",
    "summary": "HORSHAM - Johnson & Johnson today announced that the U.S. Food and Drug Administration has approved TREMFYA , the first and only IL-23 inhibitor offering both subcutaneous and intravenous ...",
    "url": "https://finnhub.io/api/news?id=2ca5c84856c00c2b804fcdb0db508a7d82099530cad2e8e90f19b920af13668e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742544760,
      "headline": "U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease",
      "id": 133297734,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "HORSHAM - Johnson & Johnson today announced that the U.S. Food and Drug Administration has approved TREMFYA , the first and only IL-23 inhibitor offering both subcutaneous and intravenous ...",
      "url": "https://finnhub.io/api/news?id=2ca5c84856c00c2b804fcdb0db508a7d82099530cad2e8e90f19b920af13668e"
    }
  },
  {
    "ts": null,
    "headline": "PBMs Are Becoming Legal Risks For Employers",
    "summary": "JPMorgan Chase & Co. is the latest major corporation to face a class action lawsuit from employees alleging mismanagement of their prescription drug benefits. The lawsuit claims that JPMorgan, through...",
    "url": "https://finnhub.io/api/news?id=f94b4ab37ee8aee446d16d54d3569f859d1608e3eb837b02d7384829b7b7635a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742544615,
      "headline": "PBMs Are Becoming Legal Risks For Employers",
      "id": 133297711,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "JPMorgan Chase & Co. is the latest major corporation to face a class action lawsuit from employees alleging mismanagement of their prescription drug benefits. The lawsuit claims that JPMorgan, through...",
      "url": "https://finnhub.io/api/news?id=f94b4ab37ee8aee446d16d54d3569f859d1608e3eb837b02d7384829b7b7635a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
    "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
    "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742541707,
      "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
      "id": 133297533,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1444529209/image_1444529209.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
      "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb"
    }
  },
  {
    "ts": null,
    "headline": "J&J plans to invest more than $55 billion in US over next four years",
    "summary": "Johnson & Johnson said onFriday it plans to invest more than $55 billion over the nextfour years to build manufacturing facilities and researchinfrastructure in the United States. The...",
    "url": "https://finnhub.io/api/news?id=4b6d2e17d0f4a74e6469be23ee53ad46ce86b8b3f5d162dfab84b2f6cdb0527a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742537533,
      "headline": "J&J plans to invest more than $55 billion in US over next four years",
      "id": 133297029,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson said onFriday it plans to invest more than $55 billion over the nextfour years to build manufacturing facilities and researchinfrastructure in the United States. The...",
      "url": "https://finnhub.io/api/news?id=4b6d2e17d0f4a74e6469be23ee53ad46ce86b8b3f5d162dfab84b2f6cdb0527a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Increases US Investment To More Than $55 Bln Over The Next Four Years",
    "summary": "Johnson & Johnson: * JOHNSON & JOHNSON INCREASES U.S. INVESTMENT TO MORE THAN$55BILLION OVER THE NEXT FOUR YEARS * JOHNSON & JOHNSON - INVESTMENT REPRESENTS 25%...",
    "url": "https://finnhub.io/api/news?id=7a36f93fced83a82688a72922f919066584f9b2ff83d744a6b2c18e3b72567f4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742537035,
      "headline": "Johnson & Johnson Increases US Investment To More Than $55 Bln Over The Next Four Years",
      "id": 133296959,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * JOHNSON & JOHNSON INCREASES U.S. INVESTMENT TO MORE THAN$55BILLION OVER THE NEXT FOUR YEARS * JOHNSON & JOHNSON - INVESTMENT REPRESENTS 25%...",
      "url": "https://finnhub.io/api/news?id=7a36f93fced83a82688a72922f919066584f9b2ff83d744a6b2c18e3b72567f4"
    }
  }
]